Grant of Options to Directors

RNS Number : 4148V

NetScientific PLC

30 January 2017

 

("NetScientific" or the "Company" or the "Group")

Grant of Options to Directors

London, UK - 30^th January 2017 - NetScientific plc ("NetScientific", AIM: NSCI), the transatlantic biomedical and healthcare technology group, today announced that on 27^th January 2017, options over ordinary shares of 5p each were granted to its CEO François Martelet and CFO Ian Postlethwaite as detailed below (the "New Options").

Director	Number of Options       Granted	Number of Options Held
François Martelet Ian Postlethwaite	200,000 180,000	759,020 360,000

The New Options have an exercise price of 65.5 pence per share, being the average closing price for the ordinary shares over the five dealing days prior to the date on which the options were granted. The New Options vest three years from the date of grant.

- Ends -

For more information, please contact:

NetScientific François R. Martelet, M.D., CEO Ian Postlethwaite, CFO	Tel: [phone]
Stifel Nicolaus Europe Limited (NOMAD and broker) Jonathan Senior / David Arch / Ben Maddison	Tel: [phone]
Consilium Strategic Communications Mary-Jane Elliott / Jessica Hodgson / Chris Welsh	Tel: [phone]  [e-mail]

About NetScientific Plc

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

END

 

 

DSHDBGDBDDDBGRC